Literature DB >> 17660957

Impaired clearance of methotrexate in organic anion transporter 3 (Slc22a8) knockout mice: a gender specific impact of reduced folates.

Adam L VanWert1, Douglas H Sweet.   

Abstract

PURPOSE: To elucidate the role of the renal basolateral transporter, Oat3, in the disposition of methotrexate.
MATERIALS AND METHODS: Chinese hamster ovary cells expressing mouse Oat3 were used to determine kinetics and specificity of inhibition of methotrexate transport. Methotrexate clearance was then examined in vivo in wildtype and Oat3 knockout mice.
RESULTS: NSAIDs, beta-lactams, and uremic toxins inhibited mOat3-mediated methotrexate uptake by 70-100%, while folate, leucovorin, and 5-methyltetrahydrofolate inhibited transport by 25-50%. A Km of 60.6 +/- 9.3 microM for methotrexate transport was determined. Oat3 knockout mice exhibited reduced methotrexate-to-inulin clearance ratios versus wildtype. Male wildtype mice, but not knockouts or females, demonstrated significantly accelerated methotrexate clearance in response to reduced folates. Reduced folates also markedly inhibited hepatic methotrexate accumulation in males, but not females, and the response was independent of Oat3 function.
CONCLUSIONS: Oat3 contributes to methotrexate clearance, but represents only one component responsible for methotrexate's elimination. Therefore, in patients, dysfunctional hOAT3 polymorphisms or drug competition for hOAT3 transport may severely impact methotrexate elimination only when redundant means of methotrexate removal are also compromised. Furthermore, the present findings suggest that reduced-folate administration only influences methotrexate disposition in males, with the renal reduced-folate response influenced by OAT3 function.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17660957      PMCID: PMC2820254          DOI: 10.1007/s11095-007-9407-0

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  31 in total

1.  Characterization of methotrexate transport and its drug interactions with human organic anion transporters.

Authors:  Michio Takeda; Suparat Khamdang; Shinichi Narikawa; Hiroaki Kimura; Makoto Hosoyamada; Seok Ho Cha; Takashi Sekine; Hitoshi Endou
Journal:  J Pharmacol Exp Ther       Date:  2002-08       Impact factor: 4.030

2.  High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations.

Authors:  Thomas Rau; Birgit Erney; Ralf Göres; Thomas Eschenhagen; Jörn Beck; Thorsten Langer
Journal:  Clin Pharmacol Ther       Date:  2006-11       Impact factor: 6.875

3.  Organic anion transporter 3 (Slc22a8) is a dicarboxylate exchanger indirectly coupled to the Na+ gradient.

Authors:  Douglas H Sweet; Lauretta M S Chan; Ramsey Walden; Xiao-Ping Yang; David S Miller; John B Pritchard
Journal:  Am J Physiol Renal Physiol       Date:  2002-12-17

4.  Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.

Authors:  S H Cha; T Sekine; J I Fukushima ; Y Kanai; Y Kobayashi; T Goya; H Endou
Journal:  Mol Pharmacol       Date:  2001-05       Impact factor: 4.436

5.  Multispecific substrate recognition of kidney-specific organic anion transporters OAT-K1 and OAT-K2.

Authors:  A Takeuchi; S Masuda; H Saito; T Abe; K Inui
Journal:  J Pharmacol Exp Ther       Date:  2001-10       Impact factor: 4.030

6.  Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice.

Authors:  Douglas H Sweet; David S Miller; John B Pritchard; Yuko Fujiwara; David R Beier; Sanjay K Nigam
Journal:  J Biol Chem       Date:  2002-05-13       Impact factor: 5.157

7.  Role of kidney-specific organic anion transporters in the urinary excretion of methotrexate.

Authors:  A Takeuchi; S Masuda; H Saito; T Doi; K Inui
Journal:  Kidney Int       Date:  2001-09       Impact factor: 10.612

Review 8.  Transport of organic anions across the basolateral membrane of proximal tubule cells.

Authors:  B C Burckhardt; G Burckhardt
Journal:  Rev Physiol Biochem Pharmacol       Date:  2003-01-30       Impact factor: 5.545

9.  Organic anion transport in choroid plexus from wild-type and organic anion transporter 3 (Slc22a8)-null mice.

Authors:  Destiny Sykes; Douglas H Sweet; Simon Lowes; Sanjay K Nigam; John B Pritchard; David S Miller
Journal:  Am J Physiol Renal Physiol       Date:  2003-12-23

10.  Quantitative evaluation of the drug-drug interactions between methotrexate and nonsteroidal anti-inflammatory drugs in the renal uptake process based on the contribution of organic anion transporters and reduced folate carrier.

Authors:  Yoshitane Nozaki; Hiroyuki Kusuhara; Hitoshi Endou; Yuichi Sugiyama
Journal:  J Pharmacol Exp Ther       Date:  2004-01-13       Impact factor: 4.030

View more
  27 in total

Review 1.  Uptake carriers and oncology drug safety.

Authors:  Jason A Sprowl; Alex Sparreboom
Journal:  Drug Metab Dispos       Date:  2013-12-30       Impact factor: 3.922

2.  PharmGKB summary: methotrexate pathway.

Authors:  Torben S Mikkelsen; Caroline F Thorn; Jun J Yang; Cornelia M Ulrich; Deborah French; Gianluigi Zaza; Henry M Dunnenberger; Sharon Marsh; Howard L McLeod; Kathy Giacomini; Mara L Becker; Roger Gaedigk; James Steven Leeder; Leo Kager; Mary V Relling; William Evans; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-10       Impact factor: 2.089

Review 3.  The organic anion transporter (OAT) family: a systems biology perspective.

Authors:  Sanjay K Nigam; Kevin T Bush; Gleb Martovetsky; Sun-Young Ahn; Henry C Liu; Erin Richard; Vibha Bhatnagar; Wei Wu
Journal:  Physiol Rev       Date:  2015-01       Impact factor: 37.312

Review 4.  Choroid Plexus and Drug Removal Mechanisms.

Authors:  Austin Sun; Joanne Wang
Journal:  AAPS J       Date:  2021-05-03       Impact factor: 4.009

5.  Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate.

Authors:  Courtney S Watts; Joseph N Sciasci; Jennifer L Pauley; John C Panetta; Deqing Pei; Cheng Cheng; Caroline M Christensen; Torben S Mikkelsen; Ching-Hon Pui; Sima Jeha; Mary V Relling
Journal:  J Pediatr Hematol Oncol       Date:  2016-08       Impact factor: 1.289

6.  The drug transporter OAT3 (SLC22A8) and endogenous metabolite communication via the gut-liver-kidney axis.

Authors:  Kevin T Bush; Wei Wu; Christina Lun; Sanjay K Nigam
Journal:  J Biol Chem       Date:  2017-08-01       Impact factor: 5.157

7.  Drug transporters on arachnoid barrier cells contribute to the blood-cerebrospinal fluid barrier.

Authors:  Kazuto Yasuda; Cynthia Cline; Peter Vogel; Mihaela Onciu; Soghra Fatima; Brian P Sorrentino; Ranjit K Thirumaran; Sean Ekins; Yoshihiro Urade; Ko Fujimori; Erin G Schuetz
Journal:  Drug Metab Dispos       Date:  2013-01-08       Impact factor: 3.922

Review 8.  Contribution of tumoral and host solute carriers to clinical drug response.

Authors:  Jason A Sprowl; Torben S Mikkelsen; Hugh Giovinazzo; Alex Sparreboom
Journal:  Drug Resist Updat       Date:  2012-03-28       Impact factor: 18.500

Review 9.  Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues.

Authors:  Rongbao Zhao; Larry H Matherly; I David Goldman
Journal:  Expert Rev Mol Med       Date:  2009-01-28       Impact factor: 5.600

10.  Organic anion transporter 3 (oat3/slc22a8) interacts with carboxyfluoroquinolones, and deletion increases systemic exposure to ciprofloxacin.

Authors:  Adam L Vanwert; Chutima Srimaroeng; Douglas H Sweet
Journal:  Mol Pharmacol       Date:  2008-04-01       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.